Subtypes of endocervical cancer: A retrospective, observational study at Charlotte Maxeke Johannesburg Academic Hospital
Main Article Content
Abstract
Background. Cervical cancer is the second most common malignancy in women, particularly in developing countries. Endocervical adenocarcinoma (ECA) is less common than cervical squamous cell carcinoma (SCC), but its incidence is increasing globally, particularly in young women. The decline in the incidence of SCC is attributed to effective screening programmes.
Objectives. To assess the prevalence of ECA and its subtypes and to describe the clinicopathological characteristics of patients with these tumours at a tertiary South African institute between 2017 and 2019.
Methods. This was a cross-sectional, descriptive study of 156 ECA patients. Following ethical clearance, demographic data, clinical information and disease characteristics were obtained from departmental histopathological reports. Descriptive statistics were used to calculate the prevalence of ECA. We analysed the association between age, Papanicolaou (Pap) smear results, human papillomavirus (HPV) status, and HIV status with ECA.
Results. The prevalence of ECA was 6.8% and it was more commonly diagnosed in younger women. HPV-associated subtypes were the most common variants. The usual type of ECA accounted for 24.4% of cases. HIV status was documented in 64.0% of cases, of which 34.0% were positive. There were no statistically significant associations between ECA subtype and HIV status (p=0.81) or between ECA subtype and Pap smear results.
Conclusion. In South Africa, the prevalence of ECA is lower compared with Western countries, reflecting inadequacies in screening modalities of ECA at primary healthcare facilities. HPV prevails as a cause of endocervical carcinoma. HPV morphologic hallmarks serve as a practical guide in classifying ECAs according to their HPV status.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJOG is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
How to Cite
References
1. Stolnicu S, Hoang L, Soslow RA. Recent advances in invasive adenocarcinoma of the cervix. Virchows Arch 2019;475(5):537-549. https://doi.org/10.1007/s00428-019-02601-0
2. Gadducci A, Guerrieri ME, Cosio S. Adenocarcinoma of the uterine cervix: Pathologic features, treatment options, clinical outcome and prognostic variables. Crit Rev Oncol/Hematol 2019;135:103-114. https://doi.org/10.1016/j.critrevonc.2019.01.
3. Missaoui N, Trabelsi A, Landolsi H, et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among tunisian women. 2010;11(3):777-78.
4. Bray F. Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries. Cancer Epidemiol Biomarkers Prevent 2005;14(9):2191-2199. https://doi.org/10.1158/1055-9965.EPI-05-0231
5. International Agency for Research on Cancer. Female Genital Tumours. Geneva: World Health Organization, 2020. https://tumourclassification.iarc.who.int/chapters/34. (accessed 21 May 2025).
6. Pirog EC. Cervical adenocarcinoma: Diagnosis of human papillomavirus-positive and human papillomavirus-negative tumors. Arch Pathol Lab Med 2017;141(12):1653-1667. https://doi.
org/10.5858/arpa.2016-0356-RA
7. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology 2002;41(3):185-207. https://doi.org/ 10.1046/j.1365- 2559.2002.01462
8. Knegt Y. Audit of cervical cancer screening and colposcopy attendance in rural South Africa. Afr J Reprod Health 2014;18(4):70-78.
9. Sahdev A. Cervical TumorsSem Ultrasound CT MRI 2010;31(5):399-413. https://doi.org/10.1053/j. sult.2010.07.004
10. Moodley M. Cervical cancer in southern Africa: The challenges. Southern Afr J Gynaecol Oncol 2009;1(1):11-13. https://doi.org/10.1080/20742835.2009.11441128
11. J. Moodley MH. Cervical cancer in South Africa: Challenges and opportunities. Cancer Detect Prevent 2006;30:361-368. https://doi.org/10.1016/j.cdp.2006.07.005
12. Sachan P, Singh M, Patel M, Sachan R. A study on cervical cancer screening using Pap smear test and clinical correlation. Asia Pac J Oncol Nurs 2018;5(3):337-341. https://doi.org/10.4103/ apjon.apjon-15-18
13. Dreyer G, Maske C, Stander M. Clinical evaluation and budget impact analysis of cervical cancer screening using cobas 4800 HPV screening technology in the public sector of South Africa. PLoS ONE 2019;14(9):e0221495. https://doi.org/10.1371/journal.pone.0221495
14. Ports KA, Haffejee F, Mosavel M, Rameshbabu A. Integrating cervical cancer prevention initiatives with HIV care in resource-constrained settings: A formative study in Durban, South Africa. Glob Pub Health 2015;10(10):1238-1251. https://doi.org/10.1080/17441692.2015.1008021
15. Wang D, Zhao C, Fu L, Liu Y, Zhang W, Xu T. Primary clear cell adenocarcinoma of the cervix: A clinical analysis of 18 cases without exposure to diethylstilbestrol. Obstet Gynecol Int 2019;2019:1-6. https://doi.org.10.1155/2019/9465375
16. Uchiyama M, Iwasaka T, Matsuo N, Hachisuga T, Mori M, Sugimori H. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix. Gynecologic Oncol 1997;65(1):23-29. https://doi.org/10.1006/gyno.1997.4613
17. Kyrgiou M, Shafi MI. Invasive cancer of the cervix. Obstet Gynaecol Reprod Med 2010;8:147-154.
https://doi.org/10.1016/j.ogrm.2013.08.005
18. Simcock B, Shafi M. Invasive cancer of the cervix. Obstet Gynaecol Reprod Med 2007;17(6):181- 187. https://doi.org/10.1016/j.ogrm.2013.08.005
19. Sekirime WK, Gray R. HIV infection among Uganda women with cervical cancer: A retrospective study. Gynecol Obstet Invest 2007;(63):222-228. https://doi.org/10.1159/000098197
20. Kahesa C, Mwaiselage J, Wabinga HR. Association between invasive cancer of the cervix and HIV-1 infection in Tanzania: The need for dual screening. BMC Pub Health 2008;(30;8):262. https://doi. org/10.1186/1471-2458-8-262
21. Odida M, Sandin S, Mirembe F, Kleter B, Quint W, Weiderpass E. HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: A case-control study. Infect Agents Cancer 2011;6(1):1-13. https://doi.org/1001186/1750-9378-6-8
22. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res 2006;1(19(1)):99-105. https://doi. org/10.1177/154407370601900120
23. Silverberg MJ, Leyden WA, Chi A, et al. Human Immunodeficiency Virus (HIV) – and non-HIV- associated immunosuppression and risk of cervical neoplasia. Obstet Gynecol 2018;131(1):47-55. https://doi.org/10.1097/AOG.0000000000002371
24. Chakravarty J, Chourasia A, Thakur M, Singh A, Sundar S, Agrawal N. Prevalence of human papillomavirus infection and cervical abnormalities in HIV-positive women in eastern India. Indian J Med Res 2016;143(1):79-85. https://doi.org/10.41.3/0971-5916.178614